U.S. Markets close in 5 hrs 2 mins

Wall Street Transcript Interview with Dr. Charles M. Baum, the President and CEO of Mirati Therapeutics, Inc. (MRTX)

67 WALL STREET, New York - September 13, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Reimbursement Trends

Companies include: Mirati Therapeutics, Inc. (MRTX) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the President and CEO of Mirati Therapeutics, Inc. (MRTX) discusses company strategy and the outlook for this vital industry:

TWST: I'm sure you're referring here to your MGCD265. In layman's terms, could you give us an overview of this technology? Is it a platform? Can it be of service to other companies looking to maximize their own research efforts?

Dr. Baum: I should give you an overview of the whole pipeline in order to clarify our approach. There are three programs that are the primary focus for the company. The first is Mocetinostat; it's also known as MGCD0103. Mocetinostat is an HDAC inhibitor, or histone deacetylase inhibitor. That program is focused on the treatment of patients with hematologic malignancies. It targets epigenetic mechanisms of cancer development, and that is one of the key attributes of many cancers, including myelodysplastic syndromes, also called MDS, and some other hematologic malignancies such as Hodgkin's and Non-Hodgkin's Lymphomas. These malignancies have a number of epigenetic changes that lead to uncontrolled growth and spread of tumor cells, which eventually leads to a patient's demise.

Mocetinostat is a bit different than the other programs, which are receptor tyrosine kinase, or RTK, inhibitors. We have two RTK programs. The first that you mentioned is MGCD265, and the other one is MGCD516. Those programs are receptor tyrosine kinase inhibitors, and the focus there is on the inhibition of pathways that drive tumor growth, differentiation and spread.

The focus for MGCD265 is on the inhibition of three pathways that are especially important to tumor growth and spread. Those pathways are Met, VEGF receptor inhibition, and the third is Axl. Those three pathways are important in a number of different solid tumors, but one good example is non-small-cell lung cancer. There are patients with non-small-cell lung cancer who have tumors that are dependent on these pathways. If you were able to inhibit each pathway simultaneously, I believe that there would be therapeutic benefit, such as better response rate and control of tumor growth. We hope that this would also translate into better progression-free survival and ultimately to overall survival.

MGCD265 is in Phase I dose escalation, and we are planning to introduce a new...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.